Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Research ArticleBrief Communications

Age Effects on Serotonin Receptor 1B as Assessed by PET

David Matuskey, Brian Pittman, Beata Planeta-Wilson, Espen Walderhaug, Shannan Henry, Jean-Dominique Gallezot, Nabeel Nabulsi, Yu-Shin Ding, Zubin Bhagwagar, Robert Malison, Richard E. Carson and Alexander Neumeister
Journal of Nuclear Medicine September 2012, 53 (9) 1411-1414; DOI: https://doi.org/10.2967/jnumed.112.103598
David Matuskey
1Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
2Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Brian Pittman
1Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Beata Planeta-Wilson
2Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Espen Walderhaug
1Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
3Department of Addiction Treatment, Oslo University Hospital, Oslo, Norway
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Shannan Henry
2Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jean-Dominique Gallezot
2Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nabeel Nabulsi
2Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yu-Shin Ding
2Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Zubin Bhagwagar
1Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
4Bristol-Myers Squibb, Wallingford, Connecticut; and
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Robert Malison
1Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard E. Carson
2Department of Diagnostic Radiology, Yale University School of Medicine, New Haven, Connecticut
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alexander Neumeister
5Department of Psychiatry, New York University School of Medicine, New York, New York
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Previous imaging studies have suggested that there is an age-related decline in brain serotonin (5-hydroxytryptamine) measures in healthy subjects. This paper addresses whether the availability of 5-hydroxytryptamine receptor 1B (5-HT1B) is seen to decrease with aging via PET imaging. Methods: Forty-eight healthy control subjects (mean age ± SD, 30 ± 10 y; age range, 18–61 y; 33 men, 15 women) underwent 11C-P943 scanning on a high-resolution PET tomograph. Regions were examined with and without gray matter masking, the latter in an attempt to control for age-related gray matter atrophy on nondisplaceable binding potential (BPND) as determined by a validated multilinear reference tissue model. Results: 5-HT1B BPND decreased in the cortex at an average rate of 8% per decade without and 9% with gray matter masking. A negative association with age was also observed in all individual cortical regions. Differences in the putamen and pallidum (positive association) were significant after adjustment for multiple comparisons. No sex- or race-related effects on 5-HT1B BPND were found in any regions. Conclusion: These findings indicate that age is a relevant factor for 5-HT1B in the cortex of healthy adults.

  • serotonin1B
  • 5-HT1B
  • PET imaging
  • [11C]P943
  • aging

Serotonin (5-hydroxytryptamine) has been implicated in the aging of the brain. Preclinical and clinical work has shown alterations in the functional and structural capacities of 5-hydroxytryptamine during aging (1,2). In translational neuroimaging, decreases with age have been found for the serotonin transporter, the 5-hydroxytryptamine receptors 1A and 2A (5-HT1A and 5-HT2A, respectively), and for cerebral glucose metabolism after administration of a selective serotonin reuptake inhibitor in many cortical areas (3–8).

Recently, evidence that aging has an effect on the 5-hydroxytryptamine system has also brought about a focus on 5-HT1B (1,9). 5-HT1B is part of the 5-HT1 family and is a G-protein–coupled metabotropic receptor spanning 7 transmembranes (10). 5-HT1B is expressed as an autoreceptor on serotoninergic neurons, where it is the predominant presynaptic modulator of 5-hydroxytryptamine release in the brain, and as a heteroreceptor on nonserotoninergic neurons (10). Although the only clinically available 5-HT1B medications are for headaches (the triptan class of 5-HT1B/D agonists), these receptors have become increasingly important in neurophysiologic functions and for behaviors as diverse as locomotor activity, drug abuse reinforcement (11), depression (12), and posttraumatic stress disorder (13), as well as learning, memory, and aggressive behavior (10).

Basic research in aging has shown large decreases (of ≤27%) in the density of 5-HT1B (5-HT1A apparently did not decrease) in elderly rats (9,14) and postsynaptic 5-HT1B messenger RNA in several brain regions (14), raising the possibility that aged animals may have relatively specific reduced 5-HT1B function. In addition, another study focused on 5-HT1B and aging and demonstrated that 5-HT1B knockout mice had an early age-related motor decline and decreased lifespan, thus increasing the plausibility that 5-HT1B is an important component of normal aging (1). An interesting finding of that paper was a comparative phylogenetic conservation of a genetic age effect from mice to humans suggesting that 5-HT1B may be a modulator of aging across species (1). To date, however, possible effects of aging on 5-HT1B have not, to our knowledge, been studied in healthy humans. The aim of this study was to investigate age effects in the brain of healthy subjects via the highly selective 5-HT1B ligand 11C-P943 using PET imaging.

MATERIALS AND METHODS

Subjects

Forty-eight healthy, medication-free volunteers were recruited through public advertisement to participate in the study. Subjects were between 18 and 61 y old (mean ± SD, 30 ± 10 y). Thirty-three (69%) were male. Thirty-seven (77%) were Caucasian, 5 (10%) were African-American, and 2 each were Hispanic, Asian-American, or multiracial. One subject (26 y old) was excluded on statistical grounds (>3 SDs above the mean cortical nondisplaceable binding potential [BPND]).

All subjects had a comprehensive screening assessment that included a complete physical examination with medical history, routine blood tests, pregnancy test, urine toxicology, and electrocardiography and a psychiatric evaluation with application of the structured clinical interview for diagnosis of axis I disorders from the Diagnostic and Statistical Manual of Mental Disorders, fourth edition. Individuals were excluded if they reported a diagnosis of current or lifetime axis I or II psychiatric disorders; current or past serious medical or neurologic illness (including a history of head injury with loss of consciousness); current pregnancy (as documented by pregnancy testing at screening and on the day of the PET study) or breast feeding; general MRI exclusion criteria; and significant alcohol or illicit substance abuse or dependence in the past 3 mo. All subjects were medication-free for a minimum of 6 wk at the time of the scan.

The study was performed under protocols approved by the Yale Human Investigation Committee, the Human Subjects Subcommittee of the Veterans Affairs Connecticut Healthcare System, the Yale University Radiation Safety Committee, the Yale–New Haven Hospital Radiation Safety Committee, and the Yale MRI Safety Committee. Subjects were recruited from New Haven and surrounding areas by advertisement, word of mouth, and referrals. Written informed consent was obtained from all participants after a full explanation of study procedures.

Radiochemistry

11C-P943 (R-1-[4-(2-methoxy-isopropyl)-phenyl]-3-[2-(4-methyl-piperazin-1-yl)benzyl]-pyrrolidin-2-one) was prepared as previously described (15) by N-methylation of the precursor with 11C-methyl triflate, using the PETtrace cyclotron and a TRACERLab FxC automated synthesizer (GE Healthcare). The GE Microlab was used in some of the preparations as a source of the requisite 11C-methyl iodide.

Scanning and Imaging Procedures

PET was performed with the selective 5-HT1B antagonist radiotracer 11C-P943. All scanning was performed on a high-resolution research tomograph (Siemens/CTI), which acquired 207 slices (1.2-mm slice separation) with a reconstructed image resolution of about 3 mm. A transmission scan with a 137Cs point source was obtained before the emission scan. The PET scans were acquired for 120 min at rest with a single intravenous injection of 630 ± 132 MBq and a high specific activity of 161 ± 71 MBq/nmol.

Structural MR images were obtained on a 3-T Trio system (Siemens Medical Solutions) with a circularly polarized head coil for each subject to exclude individuals with anatomic abnormalities and for coregistration. The dimension and voxel size of MR images were 256 × 256 × 176 and 0.98 × 0.98 × 1.0 mm, respectively.

Dynamic PET scan data were reconstructed with all corrections (attenuation, normalization, scatter, randoms, dead time, and motion), using the MOLAR algorithm (16) with the following frame timing: 6 × 30 s, 3 × 1 min, 2 × 2 min, and 22 × 5 min. Motion was additionally corrected by image smoothing with a gaussian filter of 3 mm in full width at half maximum and either by using an optical detector (Vicra; NDI Systems) or by coregistering each frame image to an early summed image (0–10 min after injection) with a 6-parameter mutual information algorithm (FLIRT, FSL 3.2; Analysis Group, FMRIB). Both motion corrections were added as a covariate in further analysis, and no significant differences were found in any of the regions studied (F1,45 = 0.01, P = 0.9144). As in previous P943 studies, PET data were used to produce a time–activity curve for the cerebellum, which was used as a reference. The multilinear reference tissue model has been previously validated in a P943 study and was used to produce parametric images of BPND (17).

A second summed image (0–10 min after injection) was created from the motion-corrected PET data and registered to the subject’s MR image, which in turn was registered (12-parameter affine transformation) to an MRI template (Montreal Neurologic Institute space).

Regions of interest were based on the Anatomic Automatic Labeling template delineated on an MRI template (18). The primary region was the cerebral cortex, which was a summed result of the frontal, occipital, parietal, and temporal cortices. A secondary analysis examined subcortical areas (amygdala, caudate, hippocampus, hypothalamus, pallidum, putamen, and thalamus). These results were obtained using individual parametric images that were resliced in template space using the PET-to-MRI and the MRI-to-template transforms.

To account for possible partial-volume effects, a binary gray matter mask (GMM) was used. For these results, individual MR images were segmented with FAST (FMRIB’s Automated Segmentation Tool, version 3.1) to obtain masking of gray matter, white matter, and cerebrospinal fluid. The individual GMMs were then applied to the regions from the Anatomic Automatic Labeling template to obtain the mean regional values limited to gray matter voxels.

Statistical Analysis

All outcomes were summarized descriptively and assessed for normality before analysis using normal probability plots and Kolmogorov test statistics. All outcomes were approximately normal. Correlations between age and 5-HT1B were calculated separately within, and averaged across, each region. A linear mixed model was used to model the independent and joint effects of age (continuous) and cortical region (within-subject factor) on BPND values. The interaction between region and age was modeled, and slopes for each cortical region were estimated post hoc. Within-subject correlations were accounted for by fitting 3 variance–covariance structures to the data (unstructured, compound symmetry, and heterogeneous compound symmetry) and then selecting the best-fitting structure according to the Bayesian information criterion. Subcortical regions were analyzed as secondary subregions and adjusted using the Bonferroni adjustment. All analyses were conducted using SAS, version 9.1 (SAS Institute Inc.).

RESULTS

Table 1 presents average 5-HT1B (±SD) BPND levels for cortical and segmented cortical gray matter regions, along with the slope and correlations with age in the 47 reported subjects. Significant negative associations between age and 5-HT1B BPND were observed in all cortical regions, and total cortical BPND averaged an 8% decline per decade studied (9% in total cortical gray matter using GMM).

View this table:
  • View inline
  • View popup
TABLE 1.

Regional Mean BPND, Correlations Between Age and 11C-P943 BPND, and Slope for Cortical Regions of Interest

The results of the primary mixed model showed an overall significant effect of age on both total BPND (F1,45 = 21.6, P < 0.0001) and total BPND after GMM (F1,45 = 28.6, P < 0.0001), averaged across all cortical regions. These effects are depicted in Figures 1 and 2, respectively. Consistent with the univariate results, primary mixed-model slope estimates for the individual 5-HT1B BPND cortical regions (with and without GMM) remained significant (P = <0.01) with age (Figs. 3 and 4, respectively).

FIGURE 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 1.

Mean cortical BPND for each subject along with age (in years).

FIGURE 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 2.

Mean cortical BPND (after GMM) for each subject along with age (in years).

FIGURE 3.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 3.

Mean BPND for each cortical region along with age (in years).

FIGURE 4.
  • Download figure
  • Open in new tab
  • Download powerpoint
FIGURE 4.

Mean BPND (after GMM) for each cortical region along with age (in years).

Subcortical region (without GMM) correlations were largely insignificant when age and 5-HT1B BPND were examined, with the exception of the hypothalamus (r = −0.28, P = 0.05), pallidum (r = +0.39, P = 0.01), and putamen (r = +0.41, P < 0.01). GMM subcortical results found a difference in the putamen (r = +0.32, P = 0.03) and a trend-level difference in the pallidum (r = +0.26, P = 0.08), with all other regions nonsignificant. Subcortical results remained significant after a multiple-comparison correction in the pallidum (Bonferroni-adjusted P = 0.05) and putamen (Bonferroni-adjusted P = 0.03) without GMM.

Sex and race had no significant effects on these results.

DISCUSSION

This work has furthered our understanding of the role of aging on the serotonin system by demonstrating age effects on 5-HT1B with the PET radiotracer 11C-P943. A decrease in BPND was found throughout cortical areas with increased age. These findings are consistent with the existing literature on aging and serotonin, which has shown decreases in the density of 5-HT1A and 5-HT2A in aging (3–6,8,19).

Different methods to control for cerebral atrophy were used in these cited studies. The current work used a gray matter segmentation to create a gray matter binary mask, and although this method is not necessarily sensitive to all partial-volume effects, the retention of findings argues against the possibility that cerebral atrophy is responsible for the decreases in 5-HT1B with aging. Furthermore, a recent study that examined 5-HT2A and aging found that a partial-volume correction was not necessary when similar parameters (cortical regions of interest, high-resolution scanning, and a healthy population) were examined (19).

Our sample comprised mostly male subjects (69%) who were younger than 61 y, and the sample was also limited in distribution across age regions (with most subjects under 40 y). This is a limitation to the current analysis, as it is susceptible to bias induced by fewer older subjects and sex (although no current sex effects were found). Further studies including a more balanced distribution of older subjects could be justified to verify that 5-HT1B decline is a linear phenomenon in advanced age. Although the multilinear reference tissue model is a validated method to examine these data, another potential limitation in this study was the lack of available arterial blood flow data in most subjects to rule out potential confounders such as age-related effects of the cerebellar time–activity curve.

The preliminary finding of increased 5-HT1B BPND in the pallidum and putamen (which retained significance after multiple corrections) could be of interest, as there are no current reports of increasing serotonin receptor brain levels with age in any region. If confirmed in further work, these subcortical areas could be a focus of a potentially novel process.

Finally, whereas the focus of this paper was to investigate age effects on 5-HT1B, the functional impact of this finding could extend into cognitive effects such as memory or learning that have been implicated in 5-HT1B decline in a host of preclinical work (1,9,14). In the only other work to date on an aged human population, postmortem examination found reduced 5-HT1B density in Alzheimer patients, compared with controls, in the frontal and temporal cortices (20). Interestingly, cognitive decline was associated with more 5-HT1B in that study. The authors attributed this finding to a compensation of 5-HT1B heteroreceptors for a deteriorated cholinergic system (i.e., the heteroreceptors, which function to inhibit acetylcholine, led to worse cognitive performance due to decreased acetylcholine in an already acetylcholine-deficient state in Alzheimer disease). It remains to be seen if 5-HT1B medications could have a clinical effect on age-specific cognitive problems, but the current results support further investigation of this potential learning and memory treatment.

CONCLUSION

The findings of this study indicate that age is a relevant factor for 5-HT1B in the cortex of healthy adults.

DISCLOSURE STATEMENT

The costs of publication of this article were defrayed in part by the payment of page charges. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

Acknowledgments

Both the P943 standard and the N-desmethyl precursor were provided by Pfizer, Inc. (Groton, CT). This project was supported by the National Institutes of Health through the following awards: R21 MH081103 (ARRA), R21 MH085627, and R21 AA018329. This project was also supported in part by the Research Council of Norway, Division for Science. Zubin Bhagwagar is a full-time employee of Bristol-Meyers Squibb. No other potential conflict of interest relevant to this article was reported.

Footnotes

  • Published online Jul. 31, 2012.

  • © 2012 by the Society of Nuclear Medicine and Molecular Imaging, Inc.

REFERENCES

  1. 1.↵
    1. Sibille E,
    2. Su J,
    3. Leman S,
    4. et al
    . Lack of serotonin1B receptor expression leads to age-related motor dysfunction, early onset of brain molecular aging and reduced longevity. Mol Psychiatry. 2007;12:1042–1056.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Meltzer CC,
    2. Reynolds CF III.
    . In vivo assessment of aging changes in serotonin function. Neuropsychopharmacology. 1999;21:323–324.
    OpenUrlCrossRefPubMed
  3. 3.↵
    1. Meltzer CC,
    2. Smith G,
    3. Price JC,
    4. et al
    . Reduced binding of [18F]altanserin to serotonin type 2A receptors in aging: persistence of effect after partial volume correction. Brain Res. 1998;813:167–171.
    OpenUrlCrossRefPubMed
  4. 4.
    1. Versijpt J,
    2. Van Laere KJ,
    3. Dumontc F,
    4. et al
    . Imaging of the 5-HT2A system: age-, gender-, and Alzheimer’s disease-related findings. Neurobiol Aging. 2003;24:553–561.
    OpenUrlCrossRefPubMed
  5. 5.
    1. Tauscher J,
    2. Verhoeff NP,
    3. Christensen BK,
    4. et al
    . Serotonin 5-HT1A receptor binding potential declines with age as measured by [11C]WAY-100635 and PET. Neuropsychopharmacology. 2001;24:522–530.
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Baeken C,
    2. D’haenen H,
    3. Flamen P,
    4. et al
    . 123I-5-I-R91150, a new single-photon emission tomography ligand for 5-HT2A receptors: influence of age and gender in healthy subjects. Eur J Nucl Med. 1998;25:1617–1622.
    OpenUrlCrossRefPubMed
  7. 7.
    1. Goldberg S,
    2. Smith GS,
    3. Barnes A,
    4. et al
    . Serotonin modulation of cerebral glucose metabolism in normal aging. Neurobiol Aging. 2004;25:167–174.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Costes N,
    2. Merlet I,
    3. Ostrowsky K,
    4. et al
    . A 18F MPPF PET normative database of 5-HT1A receptor binding in men and women over aging. J Nucl Med. 2005;46:1980–1989.
    OpenUrlAbstract/FREE Full Text
  9. 9.↵
    1. David DJ,
    2. Bourin M,
    3. Hascoet M,
    4. et al
    . Comparison of antidepressant activity in 4- and 40-week-old male mice in the forced swimming test: involvement of 5-HT1A and 5- HT1B receptors in old mice. Psychopharmacology (Berl). 2001;153:443–449.
    OpenUrlCrossRefPubMed
  10. 10.↵
    1. Sari Y
    . Serotonin1B receptors: from protein to physiological function and behavior. Neurosci Biobehav Rev. 2004;28:565–582.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Hu J,
    2. Henry S,
    3. Gallezot J-D,
    4. et al
    . Serotonin 1B receptor imaging in alcohol dependence. Biol Psychiatry. 2010;67:800–803.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Murrough JW,
    2. Henry S,
    3. Hu J,
    4. et al
    . Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder. Psychopharmacology (Berl). 2011;213:547–553.
    OpenUrlCrossRef
  13. 13.↵
    1. Murrough JW,
    2. Czermak C,
    3. Henry S,
    4. et al
    . The effect of early trauma exposure on serotonin type 1B receptor expression revealed by reduced selective radioligand binding. Arch Gen Psychiatry. 2011;68:892–900.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Mitchell ES,
    2. McDevitt RA,
    3. Neumaier JF
    . Adaptations in 5-HT receptor expression and function: implications for treatment of cognitive impairment in aging. J Neurosci Res. 2009;87:2803–2811.
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Nabulsi N,
    2. Huang Y,
    3. Weinzimmer D,
    4. et al
    . High resolution imaging of brain 5-HT1B receptors in the rhesus monkey using [11C]P943. Nucl Med Biol. 2010;37:205–214.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Johnson CA,
    2. Thada S Rodriguez,
    3. et al
    . Software architecture of the MOLAR-HRRT reconstruction engine. IEEE Nucl Sci Symp Conf Rec. 2004;6:3956–3960.
    OpenUrl
  17. 17.↵
    1. Gallezot JD,
    2. Nabulsi N,
    3. Neumeister A,
    4. et al
    . Kinetic modeling of the serotonin 5-HT(1B) receptor radioligand [11C]P943 in humans. J Cereb Blood Flow Metab. 2010;30:196–210.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Tzourio-Mazoyer N,
    2. Landeau B,
    3. Papathanassiou D,
    4. et al
    . Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single subject brain. Neuroimage. 2002;15:273–289.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Uchida H,
    2. Chow TW,
    3. Mamo DC,
    4. et al
    . Effects of aging on 5-HT2AR binding: a HRRT PET study with and without partial volume corrections. Int J Geriatr Psychiatry. 2011;26:1300–1308.
    OpenUrlCrossRefPubMed
  20. 20.↵
    1. Garcia-Alloza M,
    2. Hirst WD,
    3. Chen CPLH,
    4. et al
    . Differential involvement of 5-HT1B/1D and 5-HT6 receptors in cognitive and non-cognitive symptoms in Alzheimer’s disease. Neuropsychopharmacology. 2004;29:410–416.
    OpenUrlCrossRefPubMed
  • Received for publication January 25, 2012.
  • Accepted for publication May 9, 2012.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 53 (9)
Journal of Nuclear Medicine
Vol. 53, Issue 9
September 1, 2012
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Age Effects on Serotonin Receptor 1B as Assessed by PET
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
Age Effects on Serotonin Receptor 1B as Assessed by PET
David Matuskey, Brian Pittman, Beata Planeta-Wilson, Espen Walderhaug, Shannan Henry, Jean-Dominique Gallezot, Nabeel Nabulsi, Yu-Shin Ding, Zubin Bhagwagar, Robert Malison, Richard E. Carson, Alexander Neumeister
Journal of Nuclear Medicine Sep 2012, 53 (9) 1411-1414; DOI: 10.2967/jnumed.112.103598

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Age Effects on Serotonin Receptor 1B as Assessed by PET
David Matuskey, Brian Pittman, Beata Planeta-Wilson, Espen Walderhaug, Shannan Henry, Jean-Dominique Gallezot, Nabeel Nabulsi, Yu-Shin Ding, Zubin Bhagwagar, Robert Malison, Richard E. Carson, Alexander Neumeister
Journal of Nuclear Medicine Sep 2012, 53 (9) 1411-1414; DOI: 10.2967/jnumed.112.103598
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • CONCLUSION
    • DISCLOSURE STATEMENT
    • Acknowledgments
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • This Month in JNM
  • PubMed
  • Google Scholar

Cited By...

  • Reduced serotonin receptors and transporters in normal aging adults: a meta-analysis of PET and SPECT imaging studies
  • Age-Related Change in 5-HT6 Receptor Availability in Healthy Male Volunteers Measured with 11C-GSK215083 PET
  • Google Scholar

More in this TOC Section

  • Intraarterial Administration Boosts 177Lu-HA-DOTATATE Accumulation in Salvage Meningioma Patients
  • Head-to-Head Comparison of 68Ga-NOTA (68Ga-NGUL) and 68Ga-PSMA-11 in Patients with Metastatic Prostate Cancer: A Prospective Study
  • Assessment of P-Glycoprotein Transport Activity at the Human Blood–Retina Barrier with (R)‐11C-Verapamil PET
Show more Brief Communications

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire